The Dendritic Cell Research group is headed by Associate Professor Georgina Clark who leads a dedicated and accomplished team of Scientists, PhD and Honours Students and Administration staff.
Professor Derek Hart
Professor Hart has made major scientific and clinical contributions, particularly in relation to his special interest in dendritic cells (DC), immunotherapy and BMT. He is a Rhodes Scholar and RCPA Distinguished Fellow. Prof Hart directed the Christchurch Clinical Haematology Unit and BMT Unit and left it with a significant research reputation, including UK MRC trial participation. He completed 11 years as the inaugural Mater Medical Research Institute Director in Brisbane and created a strong translational program including clinical cell therapy trials. His team’s anti-CD83 immunosuppressive technology is being developed by the CRC- Biomarker Translation, which he co-founded. His leadership helped create the new Queensland Translational Institute.
Professor Hart recently moved to the University of Sydney to establish the DC Research Group at the ANZAC Research Institute with translational collaborative research at RPA, Westmead and Concord Hospitals. His human DC research program leads the field, including being the first to clone several CD antigens and define several human DC subsets. The Group continues to define DC cell surface antigens including important immune regulator genes and novel gene deleted mouse models. New preclinical humanized mouse models are being used to define other translational applications e.g. new DC targeted vaccines, a trial to predict AGVHD, novel anti – DC immune-suppressive agents and a new antibody for acute myeloid leukemia.
Professor Hart has published 260 peer reviewed articles with over 8032 citations. He is a member of the NHMRC Academy, co-chairs the International Society for Cell Therapy DC Committee and his Group is on the WHO/CD Committee. He chairs the Ramaciotti Foundation SAB and Institute of Glycomics Advisory Board and serves on the ABMDR Ethics Committee. Furthermore he has recently been selected as recipient of the 2012 John & Eileen Haddon Grant for Geriatric Research. Professor Hart has been invited to speak at many national and international conferences and continues to host the popular “DC Down Under” annual DC scientific symposium.
Associate Professor Georgina Clark
1989 PhD The University of Melbourne
A/Prof Clark set up Dendritic Cell Research (DCR) at the ANZAC Research Institute alongside the late Professor Derek Hart. Her interest lies in translational research developing antibodies to leucocyte surface molecules into immune therapies. The group’s translational pipeline from discovery of novel molecules (CD300 family, CD302, CD205, CD83, CMRF-56, CMRF-44) expressed by myeloid lineage cells including dendritic cells, generating new mAbs and investigating the function of the novel molecules. mAbs to CD300 molecules, CD302 and CD83 are being developed as targeted therapy for haematological malignancies including acute myeloid leukemia and lymphomas. CD83 is being developed for the prevention of immune responses leading to graft versus host disease following haematopoietic stem cell transplantation. CMRF-56 and CMRF-44 mAbs are being developed to target antigen to DC or as part of our DC cell purification platform as we develop DC vaccination for the treatment of prostate cancer and glioblastoma.
A/Prof Clark holds patent applications surrounding the IP of these mAbs and these are managed by the IP holding company, DendroCyte BioTech Pty Ltd. A/Prof Clark is a director of DendrotCyte. This provides a mechanism for the translation and commercialisation of human therapeutic antibodies.
A/Prof Clark is active member of Sydney Catalyst, contributing to their Scientific Advisory Committee, the Australasian Society for Immunology, and the Human Cell Differentiation Molecule Nomenclature Committee She chaired the International consortium for the Tenth Human Leucocyte Differentiation Antigen Workshop.
A/Prof Georgina Clark completed her PhD at the University of Melbourne in molecular immunology in the early days of cloning cell surface molecules. She continued her studies on leucocyte surface molecules undertaking postdoctoral work at the Nuffield Department of Surgery, University of Oxford, UK. Following Oxford, Dr Clark moved to the Canterbury Health Laboratories in Christchurch New Zealand and the Christchurch Medical School at University of Otago, New Zealand where she joined Professor Hart’s group studying the molecules found on the surface of dendritic cells. A/Prof Clark was instrumental in setting up the Mater Medical Research Institute in Queensland, lead a proteomics project for the Cooperative Research Centre for Biomarker Translation before joining the ANZAC Research Institute, University of Sydney in 2010.
A/Prof Clark has participated in bringing Science to the community as part of the Scientists in Schools programs and organising World Day of Immunology events.
A/Prof Clark has contributed as CI or named co-investigator on over $15M of grant funding. She has contributed to the establishment of major research startups including the MMRI, DCR at the ANZAC Research Institute and DendroCyte BioTech Pty Ltd. She has 45 publications including the seminal publications describing the CD300 family of molecules (reviewed in Clark et al., Trends in Immunol, 2009, Ju et al., Blood 2008), novel human DC subsets (Jongbloed et al, J Exp Med, 2010), new targets for haematological disease (Ju et al, J Immunol, 2017) and new CDs (Engel et al J Immunol 2016). She has been cited over 2000 times. She has been the recipient of awards such as a Young Investigator and the Jansson-Cilag Prize from the Transplantation Society of Australia.
Dr Pablo Silveira
Senior Hospital Scientist
2001 PhD The University of Sydney
Dr Silveira joined the Dendritic Cell Research Group in 2012, where his research is focussed on novel molecules on dendritic cells that can be used as therapeutic targets to control inflammation associated with haematopoietic stem cell transplantation, solid organ transplantation or autoimmune disease.
Dr Silveira was awarded his PhD from the University of Sydney in 2001 for research analysing the genetic mechanisms conferring susceptibility to autoimmune diseases. He subsequently trained as a postdoctoral scientist under Professor David Serreze at The Jackson Laboratory (Maine, USA), where he studied the role of B lymphocytes in Type 1 Diabetes. In 2003, he was awarded an NHMRC Peter Doherty fellowship to continue his work on Type 1 Diabetes in Australia, first at the Centenary Institute (Sydney, Australia) and then as head of a research group at the Garvan Institute (Sydney, Australia).
Dr Silveira’s recent publications have shown the first systematic characterization of CD83 expression in the human immune system and in lymphoma (published in the Journal of Immunology & Haematologica). His work with a xenogeneic GVHD model demonstrated the immunosuppressive properties of the therapeutic anti-CD83 monoclonal antibody 3C12C, published in Leukemia. He was invited to present this work at the International Pancreas and Islet Transplantation Association/International Xenotransplantation Association/Cell Transplant Society Joint Congress (Melbourne, Australia). He played a leading role in characterising the dendritic cell migration function of the novel C-type lectin receptor, CD302, which was published in the Journal of Immunology and was presented at the International Symposium of Dendritic Cells (Aachen, Germany). Recent work with Westmead Hospital collaborators led to the development of a new clinically relevant reduced intensity conditioning model of graft versus host disease published in Transplantation. He was invited to present this model at The Transplantation Society International Meeting (Madrid, Spain).
Dr Phillip Fromm
Senior Hospital Scientist
Cancer Institute NSW Early Career Research Fellow
University of Sydney, Concord Clinical School, Research Fellow
2011 PhD James Cook University
Dr Fromm joined DCR in 2010 and brings significant scientific expertise in clinical and pre-clinical research in the fields of inflammation and immunology-oncology with interests in the identification and characterisation of human blood dendritic cells, and the use of high dimensional single cell “big data” to understand how the immune system and cancer interacts on a cellular level. Dr Fromm has a strong focus on translational approaches to immunology, particularly in developing active immune therapies for the treatment of haematological and solid organ malignancies such as acute myeloid leukaemia, multiple myeloma and prostate cancer.
He contributes to the strong productive translational collaboration with the Haematology departments at Royal Prince Alfred and Concord Hospitals and Oncologists at the Chris O’Brien Lifehouse. His contributed his expertise to the characterisation of cell surface molecules with the Human Leukocyte Antigen Differentiation Workshop.
Dr Fromm is actively engaged with making science accessible to the community, through his ongoing involvement with volunteer donors at Concord and Royal Prince Alfred Hospitals, clinical staff interactions and communications with patient advocates (e.g. Myeloma Foundation of Australia, North Shore Prostate Cancer Support Group, Sydney Australia). He regularly participates in education programs including the world day of immunology and interviews with local media, relating to the application of DC immunotherapy in cancer.
Dr Fromm trained as a professional research scientist in Biochemistry and Molecular Biology completing a PhD in Immunology in 2011. He combined significant scientific expertise in clinical and pre-clinical research in the fields of inflammation and immunology-oncology. Dr Fromm developed a strong background in cellular immunology, which he used to answer fundamental biological questions around the role of tumor necrosis factor (TNF) and its receptors in mediating monocyte and dendritic cell development. This resulted in a major publication that was the first to describe the in vivo consequences of reverse signaling through membrane TNF via TNFR1 to promote monocyte differentiation and innate immunity to during infection (J. Immunol 188:6258). Additionally, he has also published on the role that chemokine and chemokine receptors have on B cell activation and affinity maturation of antibodies (Immunol Cell Biol 2013 May, 91(5):335-339), the regulation of dendritic cell migration through C-type lectin receptors (Immunol Cell Biol 2016, Aug ;197(3):885-898) and in dissecting the mechanism of uptake of novel heavy metal Ruthenium complexes as chemotherapeutic agents in malignant B cells (ChemMedChem 6:848).
Dr Fromm is a Cancer Institute NSW Early Career Research Fellow involved in targeting DC for use in immunotherapy in haematological and solid organ malignancies. Dr Fromm awards include; Sydney Catalyst, Best Oral Presentation (2015), Early Career Research Prize, Concord Repatriation General Hospital (2013), Australasian Society of Immunology Travel award (2009), ARC/NHMRC Research Network for Parasitology Travel award (2008), European Macrophage and Dendritic Society Travel Award (2008), Medicine Health and Molecular Science Graduate Research Scheme (2008), Logan award for Biochemistry and Molecular Biology (2008), University Medal – James Cook University (2006), Patterson Medal for Immunology (2005) and Molecular Sciences Society Prize for Biochemistry & Molecular Biology (2004 & 2005).
Dr Xinsheng Ju
Senior Hospital Scientist
1983 – 1989 Faculty of Medicine, Secondary Military Medical University, Shanghai, P. R. China. Bachelor of Medicine (MB BS, 1989)
1989 – 1992 Chinese Academy of Military Medical Science, Beijing, P. R. China, Master of Medical Science (M.Sc.1992)
Dr Ju re-joined Professor Derek Hart, Dendritic Cell Research group in 2014 to continue his long term interests on DC biology and targeting CD83 molecule to control graft versus host disease (GVHD) and treat haematological malignancies.
Dr Ju studied medicine for six years and received another three year medical science training in China, then he moved back to clinic as a haematologist. Since 1997, he continued his studies in University Hospital of Geneva (Geneva, Switzerland), Max Delbruck Centre for Molecular Medicine (Berlin, Germany) and University Hospital of RWTH (Aachen, Germany). In 1999, he was awarded German DAAD post doctor fellowship. In 2006 Dr Ju joined Professor Derek Hart’s laboratory Dendritic Cell Research Program at the Mater Medical Institute (Brisbane, Australia) focusing on studying regulatory molecule CD300a on dendritic cell function.
Dr Ju received a German DAAD post doctor fellowship from 1999 to 2001. He has published several papers in peer reviewed journals including Nature Immunol 4: 380, 2003; J Exp Med 207: 1247, 2010; Blood 112: 1184, 2008; J Immunol 192: 1982, 2014; J Immunol 197: 4613, 2016; Leukemia 30: 692, 2016; Haematologica 103: 655, 2018.
Dr Julius W. Kim
2015 Doctoral Degree, Saint Louis University, USA
Dr Kim joined the Dendritic Cell Research group in 2017 with an expertise in the fields of neurobiology, immunology, cancer -biology, and genetic engineering. His research focuses on the treatment of brain tumour, using dendritic cell based anti-cancer vaccination/immunotherapy.
He is an active member of Sydney Catalyst, Australasian Society for Immunology, American Society of Gene and Cell Therapy (ASGCT), Society of Neuro-Onocology (SNO), the Cooperative Clinical Trials Groups of the Clinical Oncological Society of Australia (COGNO), BrainStorm Brain Cancer Research Group at the Brain and Mind Centre, Royal Prince Alfred Hospital.
He is an external reviewer of NHMRC Project Grant.
Dr Kim’s first training was completed at Washington University in Saint Louis, USA. He focused on the engineering of adenoviral vectors, utilizing various genetic modifications. His novel development – ‘Porcine Knob Xenotype Chimeric Adenoviral Vector for Dendritic Cell (DC) Infection’ was patented in USA (Patent US5693509). He pursued an opportunity to further integrate his extensive portfolio of expertise in neuroscience, virology, and DC-based cancer therapy with the translational explorations for brain tumor in the laboratory of Prof Maciej S. Lesniak, at The Brain Tumor Center of The University of Chicago (Post-Doctoral fellow) and at Northwestern University (Research Associate). He has researched on various GBM-translational approaches: (1) Targeted oncolytic virotherapy, (2) Oncolytic virotherapy-mediated immune responses, (3) In vivo DC-targeted vector-mediated cancer vaccine therapy, (4) Antibody-based therapy, (5) Stem cell-based therapy and (6) Combinatory checkpoint inhibitor-based therapy.
For the past 5 years, Dr Kim has generated 25 manuscripts with 346 citations. He has received research funding from Chicago Biomedical consortium (2015) and a Postdoctoral research award on DC targeted immunotherapy. Dr Kim has been awarded the Charles B. Huggins Symposium: Awarded best presenter (2014 & 2015), The Society for Neuro-Oncology: Selected oral presenter (2014 & 2015). He has been invited to present at the Sydney Catalyst Education Dinner (2017), BrainStorm Brain Cancer Research Group (2017) and a selected oral presenter at Sydney Catalyst Post Graduate & Early Career Research Symposium (2018), 15th International Symposium on DCs (2018).
Dr Kevin (Tsun Ho) Lo
2013 Bachelor of Medical Science (Hons), University of Sydney
2018 PhD (Medicine), University of Sydney
Following completion of his PhD, Kevin has continued as a postdoctoral scientist with DCR. The skill set he has curated during his studies is being put to good use learning high end flow cytometric sorting, in vivo imaging of migrating macrophage and completing studies of monoclonal antibodies with potential to target leukemias.
Kevin is an international student from Hong Kong. He completed the Bachelor of Medical Science (Honours) degree at the University of Sydney in 2013 with the Dendritic Cell Research group. During his honours year, Kevin focused his studies on a dendritic cell surface molecule termed CD302 under the supervision of Dr Pablo Silveira and was awarded first class honours for his thesis. In the following year, Kevin commenced his PhD with the Group to further study the immunological function of CD302 and revealed its role in dendritic cell migration. He has recently submitted his PhD thesis for examination.
Kevin was awarded the Australian Research Training Program Scholarship in 2017 and had two successful applications for Postgraduate Research Support Scheme. During PhD candidature, Kevin presented his work in different leading immunology conferences, including the International Congress of Immunology and yearly at ASI Annual Meetings. He has also contributed actively to the Group’s academic outputs and resulted in one first author publication in the Journal on Immunology, which described the function of CD302 on dendritic cells, and four other team publications.
Ms Fiona Kupresanin
2003 Bachelor of Biomedical Science, University of Melbourne
2012 Master of Dietetics, Deakin University
Fiona joined the Dendritic Cell Research group in 2012 taking on the role of Laboratory Manager. She also assists technically in the areas of flow cytometry, cell culture, confocal microscopy, molecular biology and animal handling.
Fiona Kupresanin completed a Bachelor of Biomedical Science at The University of Melbourne in 2003, and more recently a Master of Dietetics degree at Deakin University. She gained several years of Research Assistant experience at The Walter and Eliza Hall Institute before joining the Dendritic Cell Research group.
Fiona has contributed to a wide range of projects leading to publications both in DCR and previously at the Walter and Eliza Hall Institute.
Ms Adelina Romano
2016 BMedSci (Hons I Physiology), University of Sydney
Adelina is a research assistant for DCR working both at the ANZAC Research Institute and the Charles Perkins Centre on University of Sydney’s central campus. At DCR, she characterises primary human dendritic cell subsets using flow cytometry and molecular techniques. With Dr Bolton, Adelina works on a mouse model using T regulatory cells to prevent graft-versus-host disease in bone marrow and T cell transplants.
In 2016, Adelina completed an undergraduate degree in Medical Science, majoring in Immunology and Biochemistry. During her Honours year, she studied a newly-identified macrophage population in the mouse yolk sac at the Blood Cell Development Laboratory, Bosch Institute, NSW. For this project she was awarded a travelling fellowship to Kyushu University, Japan, to further characterise the transcription factors regulating these cells.
Awarded a Travelling Fellowship, in Development, from the Company of Biologists (2016). Achieving a First Class Honours degree.
Ms Donna Bonnici
Donna joined DCR when it first moved to Sydney in 2010 acting as Executive Assistant to Professor Derek Hart and now Associate Professor Georgina Clark. She has contributed to setting up DCR in its new facilities and provides the support required to run a world class research group. Donna uses her skills for maintaining the research networks, completing administrative requirements for ethics, grants and students. Her event management skills are used to convene the DC DownUnder Symposium which is one of Australia key symposia dedicated to dendritic cell based diagnostics and therapeutics.
Donna has an administrative background holding roles which include Course Secretary, professional development officer and membership officer for not for profit and government organisations such as the Physiotherapy Association NSW and ACT branches and The Children’s Hospital as Westmead. She has provided office management skills to small business. She contributes to community organisations in event management and the Maltese community.
Ms Cindy (Ziduo) Li
2009 Bachelor of Biology Science, Zhejiang University, China
2013 Bachelor of Medicine, Zhejiang University, China
Her medical work in oncology departments motivated Cindy to pursue a PhD focused on discovering potent but less toxic medications for late stage cancer patients. Following relocating to Sydney in 2015, she commenced a PhD program focusing her study on evaluation of anti-CD83 monoclonal antibodies for the diagnosis and treatment of lymphomas through the Dendritic Cell Research group.
Cindy has a dual background of biological science and clinical practice with a bachelor of medicine and bachelor of biology degree. She practiced as a registered oncology physician in Beijing for three years.
Through her three years of studies, Cindy contributed to work on the basic biology of CD83 and assessment of CD83 as a potential biomarker and target for Hodgkin Lymphoma. Her work has been published in leading haematology journal Haematologica and Journal of Immunology. Cindy was also invited to give a presentation at the ASMR National Scientific Conference (2017) and Sydney Catalyst Early Career Symposium (2018). She presented her work in 2018, at the European Haematology Association Congress, a leading haematology conference.
Ms Kate (Hsiao-Ting) Chen
2005 B. Sci. Speech-Language Pathology & Audiology at Chung Shan Medical University, Taiwan
2015 Med. Science (1st class honours) at the University of Sydney
During Kate’s honour year with Dendritic Cell Research Group, she focused on characterization of a novel human CD83 knock-in mouse model to examine a potential immunosuppressive therapeutic antibody 3C12C targeting human CD83 on immune cells under the supervision of Dr Pablo Silveira. Her work was recognized and awarded the Concord Early Career Research Award in 2015.
In the following year, Kate was awarded Australian Postgraduate Award to continue as a PhD student with the group. Her current research interest is focused on characterization of the immune function of the CD300e immune regulatory molecule by using a CD300e knock-out mice model under the supervision of Associate Professor Georgina Clark.
Kate was awarded the Sydney Medical School Summer Research Scholarship in 2014 and worked in the group of Centre of Transplant and Renal Research at Westmead Millennium Institute focusing on modification and validation of the Westmead existing panels as well as the application on fresh or frozen patient samples under the supervision of Dr Min Hu.
Kate was the recipient of the Concord Repatriation General Hospital Early Career Research Award in 2015 and the University of Sydney, Australian Postgraduate Award in March 2016. In 2017 Kate received the University of Sydney, Research Training Program Stipend to present a poster at the Australian Society for Medical Research Conference in Sydney. Kate received a Concord Repatriation General Hospital Conference Travel and Postgraduate Research Support Scheme Awards in 2018 to travel to The American Association of Immunologist international conference in Austin, Texas (USA) where she presented a poster of her current experiments.
Dr Ben Kong
2002 BSc(Adv)(Hons I) University of Sydney
2006 MBBS University of Sydney
2010 Graduate Certificate in Drug Development UNSW
2015 FRACP (Medical Oncology) Royal Australasian College of Physicians
Ben joined DCR in 2015 following completion of his FRACP in Medical Oncology at Westmead Hospital. He has an interest in immunotherapy and drug development and is currently completing a PhD with the Dendritic Cell Research group investigating the pre-clinical translation of DC vaccination together with immune checkpoint inhibition for the most common primary brain cancer, glioblastoma multiforme (GBM).
Prior to training as a medical oncologist, Ben worked as a clinical trials registrar at Westmead Hospital, where he began his interest in immunotherapy whilst managing patients on early and late phase trials in solid tumours. He holds a Bachelor of Science with Honours in Physical Chemistry from the University of Sydney and has previously worked as a pharmaceutical industry analyst in the United Kingdom.
Ben presented “Towards a Dendritic Cell Vaccination for Glioblastoma Multiforme” at the Sydney Catalyst Education Dinner Series, “Dendritic Cell Vaccination for Glioblastoma Multiforme” at the University of Sydney Cancer Research Network, Brain Tumour Special Interest Group in 2017 and “Translation of DC Vaccination in Combination with Immune Checkpoint Inhibitors for Glioblastoma Multiforme (GBM)” at the Sydney Catalyst Postgraduate and Early Career Symposium in 2018. Ben has co-authored 5 publications Nature, 553:347-350, Seminars in Cell and Developmental Biology. Accepted January 2018 (in press), Oncoimmunology. 7: e1419114, Lancet Oncology, 8(9):1202-1210, J Clin Oncol 305:709-717
Dr Sarah Sutherland
Dr Sarah Sutherland is in her final year of specialist training in medical oncology at Concord Hospital and is using this year to commence her PHD investigating the use of dendritic cell vaccine strategies in prostate cancer.
Sarah completed her medical training at the University of Sydney followed by physicians training at Royal Prince Alfred Hospital (RPAH) and two years of specialist training in Medical Oncology at the Chris O’brien Lifehouse, RPAH and Concord Hospital. Sarah has a special interest in immunotherapy and the biology behind cancer development. She completed an honours project looking at the role PTEN and mTOR in the development of prostate cancer at the Garvan Institute of Medical Research during her medical degree and prior to this completed a Bachelor of Science (Adv) with a major in biochemistry at the University of Sydney.
Dr Edward Abadir
2005 Bachelor of Science, Vanderbilt University (USA)
2009 Bachelor of Medicine, Bachelor of Surgery (Honours), University of Sydney
2018 Fellowship of the Royal College of Pathologists of Australasia
2018 Fellowship of the Royal Australasian College of Physicians
Edward started his PhD with the Dendritic Cell Research Group in 2017. He has interests in malignant haematology and translational medicine. The focus of his PhD will be the development and the application of novel monoclonal antibody therapies for the treatment of acute myeloid leukaemia.
Edward completed initial medical training at the University of Sydney and his advanced training in clinical and laboratory haematology at Royal Prince Alfred and Concord Repatriation General Hospitals.
In 2018 Edward obtained his fellowships in clinical and laboratory haematology from the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. Edward has presented posters of his work at the Australian Society of Immunologist 2017 Annual Scientific Meeting in Brisbane and in 2018 at Pathology Update in Sydney. In 2018 Edward was a co-author on a scientific article published in Haematologica describing the potential of anti CD83 antibodies for the treatment of Hodgkin lymphoma
Dr Christian Bryant
Christian Bryant underwent medical training at the University of New South Wales. Following training in the speciality of Haematology at Royal Prince Alfred Hospital he commenced a PhD through the Dendritic Cell Research group and RPA Institute of Haematology Research Unit.
He has particular interests in Multiple Myeloma, tumour immunology, plasmacytoid dendritic cell biology and the translation of dendritic cell immunotherapy into clinical practice.
Dr Robin Gasiorowski
Dr Gasiorowski undertook medical training at Cambridge University and University College London before moving to Australia in 2004. Following specialist haematology training at Royal Prince Alfred and Concord Hospitals he now works as a clinical and laboratory haematologist looking after a broad range of patients with both malignant and non-malignant haematological conditions. He has a particular interest in myeloid malignancies and is currently completing a PhD with the Dendritic Cell Biology and Therapeutics Group, developing novel antibody therapies for Acute Myeloid Leukaemia. For the past two years Robin has also run the haematology teaching program for Sydney University medical students based at Concord Hospital.
Michael Papadimitrious completed his Bachelor of Science (honours) researching efflux mediated multi drug resistance of the nosocomial pathogen, Acinetobacter baumannii. Directly after his honours research, he went on to work for SA Pathology in the Human Immunology directorate where he worked in the autoimmunity, cellular immunology and allergy diagnostic laboratories.
After several years of diagnosing disease, he went on to further his research skills where he was employed by the CRC-Biomarker Translation with Professor Heddy Zola at the Women’s and Children’s Health Research Institute. It is from his experience as a research assistant that his interest in medical research developed. He then sought a PhD in translational science and commenced his PhD under the supervision of Professor Derek Hart in 2013.
His PhD research examines the development of an anti-tumour immune response by electroporating blood dendritic cells with tumour antigen mRNA. This methodology is currently being optimised with FMP mRNA and the AML antigen, WT1.
Dr Blake (Wei-Hsun) Hsu
Blake undertook his undergraduate medical training at the University of Otago in New Zealand before moving to Sydney in 2009 to commence his physicians training at Royal Prince Alfred Hospital.
Following 3 years of specialist haematology training at Royal Prince Alfred and Concord Hospitals, he is commencing a PhD programme in his final year of specialist training with the Dendritic Cell Research group. The focus of his PhD will be on a novel treatment/prevention of graft versus host disease (GVHD) following allogeneic stem cell transplant in a mouse model.